Once little more than a blip on the radar of American higher education, for-profit colleges now enroll about 1 in 10 of the nation’s postsecondary students. And this fast growth has not gone unremarked. The past year has brought unprecedented scrutiny and often harsh criticism of proprietary education from policy makers, regulators, and the news media.

Kaplan CEO Andrew Rosen argues that the current crisis provides an opportunity to place questions of student learning, innovation and cost containment at the center of higher education reform debates, and that policymakers can look to for-profit colleges for key lessons about how to retool postsecondary education to reflect new priorities.

With the cost of college rising every year, higher education alternatives such as for-profit providers have grown exponentially in recent years, offering a low-cost alternative to the traditional college model. These approaches, however, face numerous unique higher education challenges, such as persistent questions about their accreditation, the ability to transport...

At this event panelists will offer their perspective on how federal and state policy can better support the success and growth of innovations in education.

The new Obama drug initiative is of a piece with the administration's abiding faith in the virtue of government investment as a trump to private entrepreneurism. At the core of this religion is a faith that that the political allocation of capital leads to better, or at least more "equitable" outcomes.

When it comes to making the case for the niche they fill, the for-profit colleges and universities must be more proactive about showing that they do add to the common good, and they must be more transparent about how they do so.

Online communal wisdom should be harnessed for drug development.